Programmed Death Ligand 1 (PD-L1) expression in primary Angiosarcoma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Angiosarcomas are rare malignant endothelial-cell tumors of vascular or lymphatic origin, and are among the most aggressive subtypes of soft-tissue sarcomas. The prognosis is poor and treatment is challenging in many cases. PD-1/PD-L1 pathway plays a critical role in immune escape of tumor cells. Recent studies described that PD-L1 is widely expressed in various types of cancer, providing the basis for the development of PD1/PD-L1 antibodies as anti-cancer immunotherapy. Despite the well-known potential of PD-L1 as prognostic and predictive biomarker, only few studies described its IHC expression in cancer subtypes for the extreme difficulty in developing standard protocol with the different antibody clones available. We analyzed the IHC expression of PD-L1 on a series of angiosarcomas at different body location, showing its aberrant expression in about 66% of samples with no relation with prognosis. Our study allowed us to correctly define PD-L1 staining in angiosarcoma tumor tissues with final purpose to stratify patients for immune checkpoint inhibitors therapies.

Original languageEnglish
Article number19060
Pages (from-to)3166-3172
Number of pages7
JournalJournal of Cancer
Volume8
Issue number16
DOIs
Publication statusPublished - 2017

Fingerprint

Hemangiosarcoma
Ligands
Neoplasms
Endothelial Cells
Tumor Escape
Sarcoma
Immunotherapy
Anti-Idiotypic Antibodies
Clone Cells
Biomarkers
Staining and Labeling
Antibodies
Therapeutics

Keywords

  • Angiosarcoma
  • IHC evaluation
  • PD-L1

ASJC Scopus subject areas

  • Oncology

Cite this

Programmed Death Ligand 1 (PD-L1) expression in primary Angiosarcoma. / Botti, Gerardo; Scognamiglio, Giosuè; Marra, Laura; Pizzolorusso, Antonio; Di Bonito, Maurizio; De Cecio, Rossella; Cantile, Monica; De Chiara, Annarosaria.

In: Journal of Cancer, Vol. 8, No. 16, 19060, 2017, p. 3166-3172.

Research output: Contribution to journalArticle

@article{9ff6b4942a1648e69ac6a27b53ce42b5,
title = "Programmed Death Ligand 1 (PD-L1) expression in primary Angiosarcoma",
abstract = "Angiosarcomas are rare malignant endothelial-cell tumors of vascular or lymphatic origin, and are among the most aggressive subtypes of soft-tissue sarcomas. The prognosis is poor and treatment is challenging in many cases. PD-1/PD-L1 pathway plays a critical role in immune escape of tumor cells. Recent studies described that PD-L1 is widely expressed in various types of cancer, providing the basis for the development of PD1/PD-L1 antibodies as anti-cancer immunotherapy. Despite the well-known potential of PD-L1 as prognostic and predictive biomarker, only few studies described its IHC expression in cancer subtypes for the extreme difficulty in developing standard protocol with the different antibody clones available. We analyzed the IHC expression of PD-L1 on a series of angiosarcomas at different body location, showing its aberrant expression in about 66{\%} of samples with no relation with prognosis. Our study allowed us to correctly define PD-L1 staining in angiosarcoma tumor tissues with final purpose to stratify patients for immune checkpoint inhibitors therapies.",
keywords = "Angiosarcoma, IHC evaluation, PD-L1",
author = "Gerardo Botti and Giosu{\`e} Scognamiglio and Laura Marra and Antonio Pizzolorusso and {Di Bonito}, Maurizio and {De Cecio}, Rossella and Monica Cantile and {De Chiara}, Annarosaria",
year = "2017",
doi = "10.7150/jca.19060",
language = "English",
volume = "8",
pages = "3166--3172",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "16",

}

TY - JOUR

T1 - Programmed Death Ligand 1 (PD-L1) expression in primary Angiosarcoma

AU - Botti, Gerardo

AU - Scognamiglio, Giosuè

AU - Marra, Laura

AU - Pizzolorusso, Antonio

AU - Di Bonito, Maurizio

AU - De Cecio, Rossella

AU - Cantile, Monica

AU - De Chiara, Annarosaria

PY - 2017

Y1 - 2017

N2 - Angiosarcomas are rare malignant endothelial-cell tumors of vascular or lymphatic origin, and are among the most aggressive subtypes of soft-tissue sarcomas. The prognosis is poor and treatment is challenging in many cases. PD-1/PD-L1 pathway plays a critical role in immune escape of tumor cells. Recent studies described that PD-L1 is widely expressed in various types of cancer, providing the basis for the development of PD1/PD-L1 antibodies as anti-cancer immunotherapy. Despite the well-known potential of PD-L1 as prognostic and predictive biomarker, only few studies described its IHC expression in cancer subtypes for the extreme difficulty in developing standard protocol with the different antibody clones available. We analyzed the IHC expression of PD-L1 on a series of angiosarcomas at different body location, showing its aberrant expression in about 66% of samples with no relation with prognosis. Our study allowed us to correctly define PD-L1 staining in angiosarcoma tumor tissues with final purpose to stratify patients for immune checkpoint inhibitors therapies.

AB - Angiosarcomas are rare malignant endothelial-cell tumors of vascular or lymphatic origin, and are among the most aggressive subtypes of soft-tissue sarcomas. The prognosis is poor and treatment is challenging in many cases. PD-1/PD-L1 pathway plays a critical role in immune escape of tumor cells. Recent studies described that PD-L1 is widely expressed in various types of cancer, providing the basis for the development of PD1/PD-L1 antibodies as anti-cancer immunotherapy. Despite the well-known potential of PD-L1 as prognostic and predictive biomarker, only few studies described its IHC expression in cancer subtypes for the extreme difficulty in developing standard protocol with the different antibody clones available. We analyzed the IHC expression of PD-L1 on a series of angiosarcomas at different body location, showing its aberrant expression in about 66% of samples with no relation with prognosis. Our study allowed us to correctly define PD-L1 staining in angiosarcoma tumor tissues with final purpose to stratify patients for immune checkpoint inhibitors therapies.

KW - Angiosarcoma

KW - IHC evaluation

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85029672568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029672568&partnerID=8YFLogxK

U2 - 10.7150/jca.19060

DO - 10.7150/jca.19060

M3 - Article

VL - 8

SP - 3166

EP - 3172

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 16

M1 - 19060

ER -